480 related articles for article (PubMed ID: 34000225)
21. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
Arcani R; Venton G; Colle J; Suchon P; Ivanov V; Mercier C; Farnault L; Roche P; Lafage M; Brunet C; Azouza W; Pourroy B; Fanciullino R; Costello R
Eur J Haematol; 2019 Oct; 103(4):385-392. PubMed ID: 31319001
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
23. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM
BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
25. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
27. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
[TBL] [Abstract][Full Text] [Related]
28. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
Garderet L; Beohou E; Caillot D; Stoppa AM; Touzeau C; Chretien ML; Karlin L; Moreau P; Fontan J; Blaise D; Polge E; Gueye MS; Ikhlef S; Marjanovic Z; Labopin M; Mohty M
Haematologica; 2016 Nov; 101(11):1390-1397. PubMed ID: 27612987
[TBL] [Abstract][Full Text] [Related]
29. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
[TBL] [Abstract][Full Text] [Related]
30. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
O'Gorman P; Laubach JP; O'Dwyer ME; Krawczyk J; Yee AJ; Gilligan O; Cahill MR; Rosenblatt J; Quinn J; Murphy PT; DiPietro H; Perera MR; Crotty GM; Cummings K; Hayden PJ; Browne P; Savell A; O'Leary HM; O'Keeffe D; Masone K; Hennessy BJ; Guerrero Garcia T; Scott K; Saeed K; Bianchi G; Dowling P; Tierney C; Richardson PG
Am J Hematol; 2022 May; 97(5):562-573. PubMed ID: 35132679
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
[TBL] [Abstract][Full Text] [Related]
34. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
35. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
[TBL] [Abstract][Full Text] [Related]
36. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
Dosani T; Covut F; Pinto R; Kim BG; Ali N; Beck R; Maitta R; Downes K; Fox R; Reese J; de Lima M; Malek E
Leuk Lymphoma; 2019 Sep; 60(9):2199-2206. PubMed ID: 30845862
[TBL] [Abstract][Full Text] [Related]
37. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Roussel M; Lauwers-Cances V; Wuilleme S; Belhadj K; Manier S; Garderet L; Escoffre-Barbe M; Mariette C; Benboubker L; Caillot D; Sonntag C; Touzeau C; Dupuis J; Moreau P; Leleu X; Facon T; Hébraud B; Corre J; Attal M
Blood; 2021 Jul; 138(2):113-121. PubMed ID: 33827114
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
39. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
40. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
Terpos E; Kastritis E; Ntanasis-Stathopoulos I; Christoulas D; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Fotiou D; Ziogas DC; Migkou M; Roussou M; Trougakos IP; Gavriatopoulou M; Dimopoulos MA
Am J Hematol; 2019 Apr; 94(4):400-407. PubMed ID: 30592079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
